Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
© The Author(s). 2016
Received: 17 November 2016
Accepted: 28 November 2016
Published: 30 November 2016
The original article was published in Journal of Hematology & Oncology 2015 8:115
The original article  contains an omission of information in the Financial support sub-section of the Declarations section.
The authors would like to acknowledge the Andrew McDonough B+ Foundation for financial support of co-author Dr Yi-Cheng Wang throughout this study, and regret this inadvertent omission from the original publication.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Laszlo GS, et al. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. J Hematol Oncol. 2015;8:115. doi:10.1186/s13045-015-0215-4.View ArticlePubMedPubMed CentralGoogle Scholar